McQuarrie Emily P, Fellström Bengt C, Holdaas Hallvard, Jardine Alan G
Renal Research Group, University of Glasgow, Glasgow, UK.
J Ren Care. 2010 May;36 Suppl 1:136-45. doi: 10.1111/j.1755-6686.2010.00160.x.
Renal transplant recipients have a markedly increased risk of premature cardiovascular disease (CVD) compared with the general population, although considerably lower than that of patients receiving maintenance haemodialysis. CVD in transplant recipients is poorly characterised and differs from the nonrenal population, with a much higher proportion of fatal to nonfatal cardiac events. In addition to traditional ischaemic heart disease risk factors such as age, gender, diabetes and smoking, there are additional factors to consider in this population such as the importance of hypertension, left ventricular hypertrophy and uraemic cardiomyopathy. There are factors specific to transplantation such immunosuppressive therapies and graft dysfunction which contribute to this altered risk profile. However, understanding and treatment is limited by the absence of large randomised intervention trials addressing risk factor modification, with the exception of the ALERT study. The approach to managing these patients should begin early and be multifactorial in nature.
与普通人群相比,肾移植受者发生心血管疾病(CVD)的风险显著增加,尽管远低于接受维持性血液透析的患者。移植受者的心血管疾病特征尚不明确,与非肾疾病人群不同,致命性心脏事件与非致命性心脏事件的比例要高得多。除了年龄、性别、糖尿病和吸烟等传统的缺血性心脏病危险因素外,该人群还需考虑其他因素,如高血压、左心室肥厚和尿毒症心肌病的重要性。还有一些移植特有的因素,如免疫抑制治疗和移植物功能障碍,这些都导致了风险状况的改变。然而,除了ALERT研究外,由于缺乏针对危险因素调整的大型随机干预试验,对其的认识和治疗受到限制。管理这些患者的方法应尽早开始,且本质上应是多因素的。